Literature DB >> 18091176

Daily cost of glaucoma medications in China.

Ying Gao1, Lingling Wu, Aijun Li.   

Abstract

PURPOSE: To determine and compare the daily cost of various glaucoma medications in China.
MATERIALS AND METHODS: The majority of glaucoma medications commercially available in China were included in this research. The total number of drops in 1 bottle of each medication was counted drop by drop. The mean volume per bottle of each medication was calculated. The cost per drop, number of days for both eyes usage per bottle, and daily cost was calculated.
RESULTS: (1) The volume per drop ranged from 0.03 mL (brinzolamide 1%, travoprost 0.004%, bimatoprost 0.03%, and latanoprost 0.005%) to 0.05 mL (timolol 0.5%-Chengrui and pilocarpine 0.5% and 2%-Zhenrui). (2) The cost per bottle ranged from $0.69 (US dollar) (timolol 0.5%-Malaisuan Saimaluo'er) to $40.78 (latanoprost 0.005%). (3) The number of days for both eyes usage per bottle ranged from 52 days (bimatoprost 0.03%) to 11 days (pilocarpine nitrate 0.5%-Zhenrui). (4) The daily cost for both eyes usage from expensive to cheap were latanoprost 0.005%-$0.91, travoprost 0.004%-$0.77, brimonidine 0.2%-$0.61, bimatoprost 0.03%-$0.46, D-timolol 1%-$0.36, brinzolamide 1%-$0.34, pilocarpine 2%-Zhenrui-$0.28, levobunolol 0.5%-$0.25, betaxolol 0.25%-$0.24, pilocarpine 0.5%-Zhenrui-$0.18, pilocarpine 2%-Huming-$0.16, carteolol 1%-Mikelan-$0.15, carteolol 2%-Mikelan-$0.15, pilocarpine 1%-Huming-$0.10, timolol 0.5%-Chengrui-$0.08, timolol 0.5%-Malaisuan Saimaluo'er-$0.03.
CONCLUSIONS: The daily cost of glaucoma medications in China ranged much more wildly than developed countries. These data may be useful in selecting medications for glaucoma therapy. The ophthalmic solution of prostaglandins is powerful in reducing intraocular pressure. However, its high price should be considered when selecting glaucoma medications in China.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18091176     DOI: 10.1097/IJG.0b013e318064c818

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  7 in total

1.  Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China.

Authors:  Chenjia Xu; Ruru Guo; Dandan Huang; Jian Ji; Wei Liu
Journal:  J Ophthalmol       Date:  2020-07-30       Impact factor: 1.909

2.  Topical glaucoma therapy cost in Mexico.

Authors:  Gabriel Lazcano-Gomez; Alejandra Hernandez-Oteyza; María José Iriarte-Barbosa; Carlos Hernandez-Garciadiego
Journal:  Int Ophthalmol       Date:  2013-07-12       Impact factor: 2.031

Review 3.  Fixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol.

Authors:  Yuan Fang; Zhihong Ling; Xinghuai Sun
Journal:  Drug Des Devel Ther       Date:  2015-05-13       Impact factor: 4.162

4.  Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China.

Authors:  Kaidi Wang; Li Xu; Zhilan Yuan; Ke Yao; Junmei Zhao; Liang Xu; Aiwu Fang; Mingzhi Zhang; Lingling Wu; Jian Ji; Jiamin Hou; Qing Liu; Xinghuai Sun
Journal:  BMC Ophthalmol       Date:  2014-02-25       Impact factor: 2.209

5.  Cost of glaucoma treatment in a developing country over a 5-year period.

Authors:  Gabriel Lazcano-Gomez; María de Los Angeles Ramos-Cadena; Margarita Torres-Tamayo; Alejandra Hernandez de Oteyza; Mauricio Turati-Acosta; Jesús Jimenez-Román
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

6.  Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden.

Authors:  Anders Bergström; Frédérique Maurel; Claude Le Pen; Emilie Lamure; Michael Kent; Isabelle Bardoulat; Gilles Berdeaux
Journal:  Clin Ophthalmol       Date:  2009-08-20

7.  The global cost of eliminating avoidable blindness.

Authors:  Kirsten L Armstrong; Martin Jovic; Jennifer L Vo-Phuoc; Jeremy G Thorpe; Brian L Doolan
Journal:  Indian J Ophthalmol       Date:  2012 Sep-Oct       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.